Malaria and Sickle Cell Disease Treatment Market Size, Share, Growth by 2030

The market for treating malaria and sickle cell disease is projected to expand significantly, increasing from US$ 4,457.15 million in 2022 to US$ 29,179.60 million by 2030, reflecting a compound annual growth rate (CAGR) of 26.5% during this period.

This growth in the malaria and sickle cell disease treatment sector is primarily driven by the rising incidence of these conditions and enhanced governmental efforts to promote awareness regarding malaria and sickle cell disease (SCD). Nevertheless, challenges such as the prevalence of counterfeit antimalarial medications and the emergence of drug resistance are hindering market advancement.

Antimicrobial resistance poses a significant threat to public health, particularly concerning diseases like malaria. To address this issue, the development of new therapeutic agents is deemed essential. Consequently, the pipeline for antimalarial and SCD drugs and vaccines is becoming increasingly comprehensive. Collaborative efforts between public and private sectors are fostering research initiatives aimed at combating malaria and sickle cell disease. For example, the Medicines for Malaria Venture (MMV), a nonprofit organization, collaborates with various pharmaceutical companies to alleviate the malaria burden by innovating treatment solutions.

Below is a list of some antimalarial and SCD drugs/vaccines currently in clinical development:

Antimalarial Drugs/Vaccines/Compounds in Clinical Trials

Source: Company Website, The Insight Partners Analysis

Sickle Cell Disease Drugs/Vaccines/Compounds in Clinical Trials

Source: Company Website, The Insight Partners Analysis

As a result, the increasing number of antimalarial and SCD drugs and vaccines in clinical trials is anticipated to propel market growth in the coming years.

The report categorizes the malaria and sickle cell disease treatment market as follows:

The treatment market for malaria and sickle cell disease (SCD) is classified based on treatment type, administration route, distribution channels, and geographical regions. In terms of treatment type, the market is divided into malaria and sickle cell disease. Regarding the route of administration, the market is segmented into oral and parenteral methods. Distribution channels include direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. Geographically, the market is divided into North America (including the US, Canada, and Mexico), Europe (covering the UK, Germany, France, Italy, Spain, and the rest of Europe), Asia Pacific (including China, Japan, India, Australia, South Korea, and the rest of Asia Pacific), the Middle East & Africa (covering Saudi Arabia, the UAE, South Africa, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and the rest of the Middle East & Africa), and South & Central America (including Brazil, Argentina, and the rest of South & Central America).

Insights Based on Route of Administration

In terms of administration route, the malaria treatment market is divided into oral and parenteral segments. In 2022, the oral segment dominated the market share, while the parenteral segment is projected to experience a higher CAGR from 2020 to 2030. Oral drug delivery is favored due to its high patient compliance, non-invasive nature, minimal sterility requirements, cost-effectiveness, flexibility in dosage form design, and ease of manufacturing. The advantages of oral administration, including convenience and long-term cost savings, are key factors driving the preference for oral medications.

Insights Based on Distribution Channels

The malaria and sickle cell disease (SCD) treatment market is segmented by distribution channels into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment accounted for the largest market share in 2022. A tender represents a formal offer to perform specific tasks or supply goods at a predetermined price. The initial phase of a tender process involves contractors submitting sealed bids for construction or offering specifically designed services or products within a set timeframe. In India, the e-tendering process is structured to ensure timely completion of work for government or specific clients.

Key primary and secondary sources utilized in compiling the report on the malaria and sickle cell disease treatment market include the World Health Organization (WHO), the US Census Bureau, and the Centers for Disease Control and Prevention (CDC), among others.